US 10980868
VEGFR-2 targeting immunotherapy approach
granted A61KA61K2039/522A61K2039/523
Quick answer
US patent 10980868 (VEGFR-2 targeting immunotherapy approach) held by Vaximm AG expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vaximm AG
- Grant date
- Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K2039/522, A61K2039/523, A61K2039/542, A61K39/0011